Home › Esophageal Adenocarcinoma › Ohio
Esophageal Adenocarcinoma clinical trials in Ohio
12 studies for Esophageal Adenocarcinoma are looking for participants at sites in Ohio.
Cities in Ohio
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Local Institution - 0443, Cleveland
- Local Institution - 0222, Cleveland
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07221149Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Miami Valley Hospital South, Centerville
- Miami Valley Hospital, Dayton
- Premier Blood and Cancer Center, Dayton
- and 3 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06203600Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07392892Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Taussig Cancer Center, Cleveland
RecruitingHealthy volunteers welcome
Ages 50 and older · All sexes · Updated Sep 15, 2026 · NCT06687603Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
- Case Western Reserve University, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06732388Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- Cleveland VA Medical Research and Education Foundation, Cleveland
- University Hospitals Cleveland Medical Center Case Western University, Cleveland
- Cleveland Clinic Foundation, Cleveland
Recruiting
Ages 18 to 89 · All sexes · Updated Sep 11, 2026 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07431281mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Strecker Cancer Center-Belpre, Belpre
- Miami Valley Hospital South, Centerville
- Adena Regional Medical Center, Chillicothe
- and 31 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05677490A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- University of Cincinnati Cancer Center, Cincinnati
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07544589A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Maumee
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149Obeticholic Acid for Prevention in Barrett's Esophagus
- Case Western Reserve University, Cleveland
- Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland
- University Hospitals Cleveland Medical Center, Cleveland
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT04939051First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT07284186From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.